May 29 |
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
|
May 21 |
Citius gains as late-stage trial for Mino-Lok succeeds
|
May 21 |
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
|
May 14 |
Citius Pharmaceuticals Non-GAAP EPS of -$0.05
|
May 14 |
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
|
May 10 |
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
|
Apr 30 |
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
|
Apr 26 |
Citius Pharmaceuticals to raise $15M through direct offering; shares fall
|
Apr 26 |
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
|
Apr 11 |
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
|